These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2419352)

  • 21. The clinical pathophysiology of sickle cell disease.
    Embury SH
    Annu Rev Med; 1986; 37():361-76. PubMed ID: 2423018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
    Manning JM; Acharya AS
    Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Covalent chemical modifiers of sickle cell hemoglobin.
    Ueno H; Bai Y; Manning JM
    Ann N Y Acad Sci; 1989; 565():239-46. PubMed ID: 2774426
    [No Abstract]   [Full Text] [Related]  

  • 24. Enhanced survival of sickle erythrocytes upon treatment with glyceraldehyde.
    Benjamin LJ; Manning JM
    Blood; 1986 Feb; 67(2):544-6. PubMed ID: 3942837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract]   [Full Text] [Related]  

  • 26. Sickle cell anemia. Pathophysiology and treatment.
    Alavi JB
    Med Clin North Am; 1984 May; 68(3):545-56. PubMed ID: 6205230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myths and facts...about sickle-cell disease.
    Perry V
    Nursing; 2005 Dec; 35(12):27. PubMed ID: 16331199
    [No Abstract]   [Full Text] [Related]  

  • 28. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 29. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(15):804-11. PubMed ID: 692564
    [No Abstract]   [Full Text] [Related]  

  • 30. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
    Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P
    Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960
    [No Abstract]   [Full Text] [Related]  

  • 31. Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia?
    Lemonne N; Lamarre Y; Romana M; Mukisi-Mukaza M; Hardy-Dessources MD; Tarer V; Mougenel D; Waltz X; Tressières B; Lalanne-Mistrih ML; Etienne-Julan M; Connes P
    Blood; 2013 Apr; 121(15):3054-6. PubMed ID: 23580637
    [No Abstract]   [Full Text] [Related]  

  • 32. Sickle cell anemia and antisickling agents then and now.
    Mehanna AS
    Curr Med Chem; 2001 Feb; 8(2):79-88. PubMed ID: 11172667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Implications of the Association of Fetal Hemoglobin with Peripheral Oxygen Saturation in Sickle Cell Disease.
    Abdulmalik O; Ataga KI
    EBioMedicine; 2017 Oct; 24():26-27. PubMed ID: 28890145
    [No Abstract]   [Full Text] [Related]  

  • 35. The delay time in sickle cell disease after 40 years: A paradigm assessed.
    Ferrone FA
    Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane-bound hemoglobin in the erythrocytes of sickle cell anemia.
    Sears DA; Luthra MG
    J Lab Clin Med; 1983 Nov; 102(5):694-8. PubMed ID: 6631167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
    Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB
    Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 39. Review: selective filtration--a phlebotomy strategy for sickle cell therapy.
    Nusbaum NJ
    Am J Med Sci; 1995 Dec; 310(6):264-6. PubMed ID: 7503109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
    Berkowitz LR; Orringer EP
    Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.